FIELD: biotechnology.
SUBSTANCE: method for the production of natural killer cells is disclosed. The method includes isolation of peripheral blood mononuclear cells (hereinafter – PBMC) from a blood sample; isolation of at least one of CD56+ cells and/or CD3-/CD56+ cells from PBMC; and co-cultivation of at least one of CD56+ cells and/or CD3-/CD56+ cells with a combination of feeding cells in the presence of at least two cytokines, characterized in that the combination of feeding cells contains irradiated Jurkat cells and irradiated cells of an Epstein-Barr virus-transformed lymphocyte continuous line (EBV-LCL), and at least two cytokines are IL-2 and IL-21. A composition for administration to a patient in need for treatment with NK cells is also disclosed, including: NK cells multiplied in a culture in accordance with the specified method; and a pharmaceutically acceptable carrier, characterized in that multiplied NK cells have a higher level of cytotoxicity and/or anticancer activity. In addition, a method for the reproduction of NK cells in a culture is described, including: isolation of peripheral blood mononuclear cells (PBMC) from a blood sample; isolation of at least one of CD56+ cells and/or CD3-/CD56+ cells from PBMC; and co-cultivation of at least one of CD56+ cells and/or CD3-/CD56+ cells with a combination of feeding cells in the presence of at least two cytokines, characterized in that the combination of feeding cells contains irradiated Jurkat cells and irradiated cells of an Epstein-Barr virus-transformed lymphocyte continuous line (EBV-LCL), and at least two cytokines are IL-2 and IL-21, and at the same time, feeding cells and cytokines are added at certain intervals throughout the reproduction in a culture.
EFFECT: invention makes it possible to obtain natural killer cells of high purity.
38 cl, 9 tbl, 21 ex, 14 dwg
